Advances in Preventive Medicine

Review Article

Conjugate Meningococcal Vaccines Development: GSK Biologicals Experience

Table 6

rSBA-MenA, rSBA-MenC, rSBA-MenW-135, and rSBA-MenY antibody response one month after MenACWY-TT vaccination in children and adolescents (ATP immunogenicity cohort).


Reference	Age group	Vaccine		VRR	[95% CI]		GMT	[95% CI]

rSBA-MenA

Østergaard et al., 2009 [86]	15–19 years	MenACWY-TT	23	87.0	[66.4–97.2]	24	9264	[6342–13532]
Østergaard et al., 2009 [86]	15–19 years	ACWY-PS	23	78.3	[56.3–92.5]	25	8284	[6035–11370]
Knuf et al., 2010 [87]	3–5 years	MenACWY-TT	40	92.5	[79.6–98.4]	49	8299.4	[6734.2–10228.4]
Knuf et al., 2010 [87]	3–5 years	ACWY-PS	31	80.6	[62.5–92.5]	33	3798.4	[2888.9–4994.2]
Bermal et al., 2011 [88]	11–17 years	MenACWY-TT	615	85.4	[82.3–88.1]	752	6106.8	[5739.5–6497.6]
Bermal et al., 2011 [88]	11–17 years	ACWY-PS	215	79.5	[73.5–84.7]	252	3203.0	[2854.1–3594.6]

rSBA-MenC

Østergaard et al., 2009 [86]	15–19 years	MenACWY-TT	24	95.8	[78.9–99.9]	24	4329	[2404–7795]
Østergaard et al., 2009 [86]	15–19 years	ACWY-PS	24	91.7	[73.0–99.0]	25	1567	[757–3245]
Knuf et al., 2010 [87]	3–5 years	MenACWY-TT	47	93.6	[82.5–98.7]	49	1577.8	[1123.5–2215.9]
Knuf et al., 2010 [87]	3–5 years	ACWY-PS	32	81.3	[63.6–92.8]	34	445.4	[263.3–753.3]
Bermal et al., 2011 [88]	11–17 years	MenACWY-TT	719	97.1	[95.6–98.2]	754	12645.5	[11531.8–13866.7]
Bermal et al., 2011 [88]	11–17 years	ACWY-PS	237	96.6	[93.5–98.5]	252	8271.6	[6937.3–9862.4]

rSBA-MenW-135

Østergaard et al., 2009 [86]	15–19 years	MenACWY-TT	23	91.3	[72.0–98.9]	24	4422	[2939–6653]
Østergaard et al., 2009 [86]	15–19 years	ACWY-PS	25	96.0	[79.6–99.9]	25	3486	[2447–4967]
Knuf et al., 2010 [87]	3–5 years	MenACWY-TT	47	100	[92.5–100]	49	5987.2	[4846.9–7395.7]
Knuf et al., 2010 [87]	3–5 years	ACWY-PS	32	96.9	[83.8–99.9]	34	1811.1	[1233.3–2659.5]
Bermal et al., 2011 [88]	11–17 years	MenACWY-TT	717	96.5	[94.9–97.7]	759	8390.1	[7777.8–9050.7]
Bermal et al., 2011 [88]	11–17 years	CWY-PS	242	88.0	[83.2–91.8]	252	2679.3	[2363.7–3037.2]

rSBA-MenY

Østergaard et al., 2009 [86]	15–19 years	MenACWY-TT	24	79.2	[57.8–92.9]	24	2756	[2023–3755]
Østergaard et al., 2009 [86]	15–19 years	ACWY-PS	25	88.0	[68.8–97.5]	25	3056	[1892–4937]
Knuf et al., 2010 [87]	3–5 years	MenACWY-TT	48	100	[92.6–100]	49	6433.0	[4921.0–8409.6]
Knuf et al., 2010 [87]	3–5 years	ACWY-PS	34	79.4	[62.1–91.3]	34	1435.5	[972.6–2118.7]
Bermal et al., 2011 [88]	11–17 years	MenACWY-TT	737	93.1	[91.0–94.8]	758	13865.2	[12968.1–14824.4]
Bermal et al., 2011 [88]	11–17 years	ACWY-PS	246	78.0	[72.3–83.1]	252	5245.3	[4644.2–5924.1]

: numbers of subjects with available data, 95% CI: 95% confidence interval, GMT: geometric mean titre, VRR: vaccine response rate, Vaccine response defined as: (1) for initially seronegative subjects, antibody titres ≥1 : 32 at one month after vaccination, (2) for initially seropositive subjects, antibody titres at one month after vaccination ≥4-fold the pre-vaccination antibody titre, Results of this table were previously published [86–88].